Metformin XR plus placebo + Metformin XR plus liraglutide

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Gestational Diabetes Mellitus

Conditions

Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation

Trial Timeline

Aug 11, 2011 → Jun 14, 2019

NCT ID

NCT01234649

About Metformin XR plus placebo + Metformin XR plus liraglutide

Metformin XR plus placebo + Metformin XR plus liraglutide is a phase 3 stage product being developed by Novo Nordisk for Gestational Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01234649. Target conditions include Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome.

What happened to similar drugs?

5 of 9 similar drugs in Gestational Diabetes Mellitus were approved

Approved (5) Terminated (1) Active (3)

✅Insulin LISPRO + Insulin, Long-Acting and InsulinEli LillyApproved

✅Metformin + placeboNovo NordiskApproved

✅Liraglutide + PlaceboNovo NordiskApproved

✅Genotropin (somatropin)PfizerApproved

✅OmnitropeSandoz GroupApproved

🔄somatropinEli LillyPhase 3

❌Recombinant human growth hormone (r-hGH)MerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01234649	Phase 3	Completed	Aug 11, 2011	Jun 14, 2019	Gestational Diabetes Mellitus

Competing Products

18 competing products in Gestational Diabetes Mellitus

See all competitors

Product	Company	Stage	Hype Score
somatropin	Eli Lilly	Phase 3	40
Insulin LISPRO + Insulin, Long-Acting and Insulin	Eli Lilly	Approved	43
Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B	Jiangsu Hengrui Medicine	Phase 2	42
Pembrolizumab Injection [Keytruda]	Merck	Phase 2	31
recombinant somatropin	Merck	Pre-clinical	26
Recombinant human growth hormone (r-hGH)	Merck	Phase 3	32
Avelumab Injection + Methotrexate 1 GM Injection	Merck	Phase 1/2	39
Saizen® + Saizen®	Merck	Phase 3	40
Metformin + placebo	Novo Nordisk	Approved	39
Somapacitan + Norditropin®	Novo Nordisk	Phase 2	39
Liraglutide + Placebo	Novo Nordisk	Approved	43
Genotropin (PN-180,307) Somatropin + Control-no treatment	Pfizer	Phase 3	40
growth hormone	Pfizer	Pre-clinical	26
Somatropin	Pfizer	Pre-clinical	26
Somatropin	Pfizer	Pre-clinical	26
Genotropin (somatropin)	Pfizer	Approved	43
Omnitrope	Sandoz Group	Approved	40
Inhaled Technosphere Insulin	MannKind Corp	Phase 2/3	39